Atezolizumab After Vemurafenib and Cobimetinib Shows Trend Toward Better OS in Melanoma
Early switch to atezolizumab after vemurafenib plus cobimetinib showed improved OS at 4 and 5 years for BRAF V600-positive melanoma patients, though not statistically significant. Rapid progression after early switch to immune checkpoint inhibition was observed in many patients. Median OS was 40.2 months in continuous targeted therapy vs 49.6 months in atezolizumab group. No subgroups benefited from targeted therapy run-in.
Reference News
Early switch to atezolizumab after vemurafenib plus cobimetinib showed improved OS at 4 and 5 years for BRAF V600-positive melanoma patients, though not statistically significant. Rapid progression after early switch to immune checkpoint inhibition was observed in many patients. Median OS was 40.2 months in continuous targeted therapy vs 49.6 months in atezolizumab group. No subgroups benefited from targeted therapy run-in.